Speed at rest.

Still Velocity designs novel synthetic protein excipients using a computational discovery platform, identifying molecules with the potential to reduce dependence on the pharmaceutical cold chain and improve worldwide access to life-saving therapeutics.

Modern biotechnology can create extraordinary medicines, vaccines, and therapies — but many remain physically fragile, dependent on cold-chain logistics and narrow handling conditions. We build computationally designed protein materials to make fragile biologics more stable, accessible, and deployable, without compromising safety, quality, or public health.

Read the full overview →

Still Velocity is a research and intellectual property company. We design novel proteins computationally, validate them experimentally, protect them through patents, and license them to the companies that bring therapeutics to market. Still Velocity is a member of the NVIDIA Inception program, with access to NVIDIA’s BioNeMo platform, DGX Cloud compute, and technical advisory resources for AI-driven protein design.

Our first program targets the $42 billion pharmaceutical cold chain — the temperature-controlled infrastructure required to store and transport biologics worldwide. An estimated $35 billion in product is lost annually to temperature excursions. We are designing synthetic proteins that form protective bioglasses at ambient temperature, potentially eliminating cold chain dependency for entire classes of therapeutics.

The approach is capital-efficient by design. Computational protein design and molecular dynamics simulation replace years of directed evolution. Provisional patents protect each generation of candidates. Contract research organizations provide experimental validation without fixed laboratory overhead. The result is a Phase 0 model: compute, validate, patent, license.

The same computational platform extends across protein-design domains. High-concentration biologic formulation, ambient-stable cell and gene therapies, and agricultural stress-tolerance reagents are within the patented scope of our computational design platform.

Certain organisms survive complete desiccation through a class of intrinsically disordered proteins. These proteins undergo a reversible phase transition from soluble disorder to protective bioglass, physically encasing biological cargo during water loss. Upon rehydration, they return to solution and release their payload intact.

We computationally design synthetic analogs of these proteins — novel sequences with less than 50% identity to any natural protein, engineered to preserve the biophysical properties that drive vitrification while optimizing for manufacturability, stability, and regulatory compatibility. Each candidate is computationally simulated, scored, and ranked for experimental validation.

More than five U.S. provisional patent applications have been filed covering the computational design methodology, the discovery engine, and novel synthetic protein compositions. Over 5,000 candidate sequences have been computationally designed and scored, with a lead panel selected for experimental validation. Gene synthesis is underway, with experimental characterization beginning in collaboration with an academic research partner.

The pharmaceutical cold chain — the temperature-controlled infrastructure required to store and transport vaccines, biologics, and cell therapies — costs an estimated $42 billion annually and fails routinely in the regions that need it most. In sub-Saharan Africa, South Asia, and island nations, temperature excursions destroy up to 50% of vaccine doses before they reach patients.

Ambient-temperature stabilization would fundamentally restructure global pharmaceutical logistics. A biologic that ships at room temperature can reach any clinic, any village, any disaster zone — without refrigerated trucks, generator-powered cold rooms, or the constant risk of a broken link in the chain. This is not an incremental improvement. It is a category change in who medicines can reach.

Still Velocity's synthetic vitrification proteins are designed for this problem. If our candidates form protective bioglasses as predicted, entire classes of temperature-sensitive therapeutics could be reformulated for ambient distribution — starting with the vaccines and biologics that fail most often in transit.

Still Velocity collaborates with leading academic researchers in protein biophysics. Experimental characterization of our computationally designed candidates is conducted in partnership with an academic research laboratory.

Our computational platform leverages NVIDIA’s BioNeMo and DGX Cloud infrastructure through the NVIDIA Inception Program, providing AI-driven protein modeling, GPU-accelerated molecular dynamics, and technical advisory resources that compress the design-simulate-score loop from months to days.